Morningstar

Bausch & Lomb Corp BLCO

Morningstar Rating
Unlock
Stock XTSE Rating as of
—
View Full Chart
As of Delayed Price

Company Report

View Archive

Bausch & Lomb: Interested Buyers Prepare Bids as Potential Sale Work Underway

Keonhee Kim

The Financial Times reported on Sept. 18 that a number of private equity firms, including Blackstone, Advent International, and TPG, are considering offers for Bausch & Lomb. While there is no guarantee that the firm will be sold off, this increasingly looks to be a more likely option than a spinoff, given that Bausch Health—Bausch & Lomb’s parent company, which owns about 88% of its subsidiary—could use the proceeds to pay down its USD 21.2 billion in long-term debt.

Read Full Report

Price vs Fair Value

View History
BLCO is trading at a 154% premium.
Price
CAD 25.56
Fair Value
CAD 93.00
Uncertainty
High
1-Star Price
CAD 89.10
5-Star Price
CAD 52.30
Economic Moat
Vygbgph
Capital Allocation
Mclmvqh

Bulls Say, Bears Say

Bulls

As a standalone public company, Bausch now has the ability to freely allocate financial resources to innovate and develop businesses that were underfunded under its former parent company.

Bears

Bausch will face margin pressures from upcoming losses of exclusivity on its pharmaceuticals, and this might hinder its efforts to raise margins to a level comparable with that of its close competitors.

Show More

News

View All

Trading Information

Previous Close Price
—
Day Range
—–—
52-Week Range
—–—
Bid/Ask
— / —
Market Cap
—
Volume/Avg
— / —

Key Statistics

Price/Earnings (Normalized)
27.87
Price/Sales
1.47
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Core
Total Number of Employees
13,300
Website
https://www.bausch.com

Competitors

Valuation

View More
Metric
BLCO
COO
AFX
Price/Earnings (Normalized)
 27.8731.1231.78
Price/Book Value
 1.012.763.03
Price/Sales
 1.475.773.06
Price/Cash Flow
 29.8323.1719.49
Price/Earnings
BLCO
COO
AFX

Financial Strength

Metric
BLCO
COO
AFX
Quick Ratio
 0.760.882.34
Current Ratio
 1.651.993.51
Interest Coverage
 0.285.5812.08
Quick Ratio
BLCO
COO
AFX

Profitability

Metric
BLCO
COO
AFX
Return on Assets (Normalized)
 1.77%3.02%—
Return on Equity (Normalized)
 3.37%4.67%—
Return on Invested Capital (Normalized)
 4.88%4.23%—
Return on Assets
BLCO
COO
AFX

Medical Instruments & Supplies Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
VllvhlcmCxd$170.3 Bil
 Becton Dickinson & Co
BDX
XgktrhxfRgfzwsk$69.8 Bil
 Alcon Inc
ALC
FvltwfllFzpnlhp$49.3 Bil
 ResMed Inc
RMD
ZxrhqvmvgcZgyqfx$35.1 Bil
 Coloplast AS ADR
CLPBY
QjlvdhxkdbZqy$29.7 Bil
 West Pharmaceutical Services Inc
WST
HxlhvqybdlPjyjp$22.6 Bil
 The Cooper Companies Inc
COO
WzyxtgpgKhrjvw$21.9 Bil
 Baxter International Inc
BAX
JtyqrhwvgHzjxz$19.9 Bil
 Align Technology Inc
ALGN
YhvzxjtVqyzmx$19.0 Bil
 Hologic Inc
HOLX
KynsskqwPjrwzz$18.8 Bil

Sponsor Center